Spots Global Cancer Trial Database for combination therapy
Every month we try and update this database with for combination therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | NCT00401427 | Metastatic Brea... | trastuzumab vinorelbine | 18 Years - | National Cancer Institute, Naples | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | NCT06119217 | Pancreatic Canc... | TTX-030, nab-pa... TTX-030, budiga... Nab-Paclitaxel ... | 18 Years - | Trishula Therapeutics, Inc. | |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03321890 | Peripheral T-ce... | Chidamide prednisone Cyclophosphamid... etoposide Methotrexate | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | NCT03475004 | Colorectal Canc... Metastatic Canc... | Pembrolizumab Bevacizumab Binimetinib | 18 Years - 99 Years | University of Colorado, Denver | |
| Combination Therapy for Recurrent Ovarian Cancer | NCT05610735 | Recurrent Ovari... | DOXIL Withaferin A Ashwagandha Combination of ... | 18 Years - | University of Louisville | |
| Combination Therapy for Recurrent Ovarian Cancer | NCT05610735 | Recurrent Ovari... | DOXIL Withaferin A Ashwagandha Combination of ... | 18 Years - | University of Louisville | |
| CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer | NCT00330746 | Advanced Non-Sm... | cetuximab gemcitabine gemcitabine cetuximab | 18 Years - | National Cancer Institute, Naples | |
| Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | NCT05163106 | Breast Cancer HER2-negative B... ER-positive Bre... Locally Advance... Luminal A Breas... Luminal B Breas... | Letrozole 2.5mg... Goserelin | 18 Years - | University Hospital, Akershus | |
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma | NCT05755828 | B-cell Lymphoma | ASCT+CAR-T Cell... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy | NCT05361798 | Cancer Of Prost... | M9241 Stereotactic Bo... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | NCT03475004 | Colorectal Canc... Metastatic Canc... | Pembrolizumab Bevacizumab Binimetinib | 18 Years - 99 Years | University of Colorado, Denver | |
| TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria | NCT05883176 | Hepatocellular ... | Bevacizumab Bio... | 18 Years - 70 Years | Sun Yat-sen University | |
| Metformin and Simvastatin Use in Bladder Cancer | NCT02360618 | Bladder Cancer | Metformin Simvastatin | 18 Years - 85 Years | London Health Sciences Centre | |
| Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma | NCT00277017 | Kidney Cancer | 5-Flourouracil,... | - | New Mexico Cancer Care Alliance | |
| Naltrexone and Propranolol Combined With Immunotherapy | NCT05968690 | Advanced Melano... | Propranolol Naltrexone | 18 Years - | Rutgers, The State University of New Jersey | |
| A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT02763319 | Diffuse Large B... | Rituximab (RTX) Tafasitamab Bendamustine (B... | 18 Years - | MorphoSys AG | |
| Phase I Trial of Combination of FOLFIRI and SOM 230 | NCT01434069 | Gastrointestina... | SOM230C LAR FOLFIRI Infusio... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer | NCT00857246 | Gastric Cancer Stomach Cancer | Cetuximab Irinotecan Cisplatin Surgery 5-FU Radiation | 18 Years - | NYU Langone Health | |
| Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | NCT03321890 | Peripheral T-ce... | Chidamide prednisone Cyclophosphamid... etoposide Methotrexate | 18 Years - 75 Years | Sun Yat-sen University | |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | NCT00553189 | Solid Tumors Lymphomas | ABT-888 Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer | NCT03983057 | Pancreatic Canc... | Anti-PD-1 monoc... | 18 Years - 70 Years | Zhejiang University | |
| Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | NCT01572480 | Multiple Myelom... | Carfilzomib Revlimid Dexamethasone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | NCT05281471 | Platinum-resist... Platinum-refrac... Fallopian Tube ... Primary Periton... High-grade Sero... Endometrioid Ov... Ovarian Clear C... | olvimulogene na... Platinum chemot... Non-platinum ch... Bevacizumab (or... | 18 Years - | Genelux Corporation | |
| Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | NCT01421017 | Breast Cancer Metastatic Brea... Recurrent Breas... | Radiation Imiquimod Cyclophosphamid... | 18 Years - | NYU Langone Health | |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | NCT03075462 | Ovarian Cancer Triple Negative... | Fluzoparib Apatinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| SW-682 in Advanced Solid Tumors | NCT06251310 | Advanced Solid ... Mesothelioma, M... | SW-682 Combination The... | 18 Years - | SpringWorks Therapeutics, Inc. | |
| Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | NCT01889420 | Multiple Myelom... | Combination the... | 18 Years - | New Mexico Cancer Care Alliance | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) | NCT05650476 | Metastatic Cast... | Talazoparib | 18 Years - | Pfizer | |
| Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer | NCT04592666 | Lung Cancer, No... EGFR T790M EGFR Gene Mutat... | Almonertinib Pemetrexed Carboplatin | 18 Years - 75 Years | Fudan University | |
| Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors | NCT03081923 | Germ Cell Tumor | Durvalumab Tremelimumab | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | NCT05949632 | Advanced Solid ... | INCB099280 axitinib | 18 Years - | Incyte Corporation | |
| Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors | NCT00888043 | Solid Tumors | CNTO 95 and ava... | 18 Years - | Duke University | |
| Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma | NCT04413734 | Intrahepatic Ch... | Combination the... Mono-chemothera... | 18 Years - 80 Years | Zhejiang University | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors | NCT02723864 | Neoplasms | Veliparib + VX-... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | NCT04306900 | Solid Tumor, Ad... | TTX-030, budiga... TTX-030, budiga... TTX-030 and mFO... TTX-030 and bud... TTX-030, budiga... TTX-030 and pem... TTX-030, nab-pa... Budigalimab and... | 18 Years - 110 Years | Trishula Therapeutics, Inc. | |
| Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors | NCT04669899 | Cancer | JTX-8064 pimivalimab | 18 Years - | Jounce Therapeutics, Inc. | |
| Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma | NCT05907512 | Clinical Stage ... Clinical Stage ... | Endostar Toripalimab | 18 Years - 75 Years | Fudan University | |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | NCT00861419 | Advanced Solid ... | Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386 | 18 Years - | Amgen | |
| Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder | NCT02621151 | Muscle-invasive... | Pembrolizumab Transurethral R... Gemcitabine External Beam R... | 18 Years - | NYU Langone Health | |
| A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours | NCT05537051 | Advanced Solid ... | PM1021, PM8001 | 18 Years - 75 Years | Biotheus Inc. | |
| Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer | NCT01938456 | Lung Cancer, No... | Trametinib Docetaxel Filgrastim | 20 Years - | GlaxoSmithKline | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Survival Analysis: TACE vs. Combination Therapy in HCC | NCT06261138 | Hepatocellular ... | Transarterial c... Systemic treatm... | 18 Years - 75 Years | Zhejiang University | |
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | NCT03610971 | Chronic Phase C... Chronic Myeloid... | Ruxolitinib BCR-ABL Tyrosin... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) | NCT00387387 | Neoplasms, Colo... | Pazopanib FOLFOX 6 CapeOx | 21 Years - | GlaxoSmithKline | |
| Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | NCT03647488 | Carcinoma, Non-... | Capmatinib Spartalizumab Docetaxel | 18 Years - | Novartis | |
| Survival Analysis: TACE vs. Combination Therapy in HCC | NCT06261138 | Hepatocellular ... | Transarterial c... Systemic treatm... | 18 Years - 75 Years | Zhejiang University | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | NCT05025085 | Advanced Cancer | AGEN1777 a PD-1 inhibito... | 18 Years - | Bristol-Myers Squibb | |
| CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer | NCT00330746 | Advanced Non-Sm... | cetuximab gemcitabine gemcitabine cetuximab | 18 Years - | National Cancer Institute, Naples | |
| Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer | NCT03983057 | Pancreatic Canc... | Anti-PD-1 monoc... | 18 Years - 70 Years | Zhejiang University | |
| Study of AGEN1571 in Participants With Advanced Solid Tumors | NCT05377528 | Advanced Solid ... | AGEN1571 Balstilimab Botensilimab | 18 Years - | Agenus Inc. | |
| TIPS Plus Cadonilimab in Advanced HCC With Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | NCT05882370 | Hepatocellular ... | Cadonilimab transjugular in... | 18 Years - 75 Years | Sun Yat-sen University | |
| Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole | NCT05163106 | Breast Cancer HER2-negative B... ER-positive Bre... Locally Advance... Luminal A Breas... Luminal B Breas... | Letrozole 2.5mg... Goserelin | 18 Years - | University Hospital, Akershus | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| SOM 230 and Gemcitabine in Advanced Pancreatic Cancer | NCT01385956 | Pancreatic Canc... | SOM 230 LAR Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | NCT04574583 | Metastatic Canc... Solid Tumors | SX-682 M7824 MVA-BN-CV301 recombinant fow... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | NCT04933539 | Multiple Myelom... | Dexamethasone Carfilzomib Daratumumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | NCT03388632 | Metastatic Soli... Treatment-Refra... | rhIL-15 Ipilimumab Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | NCT00861419 | Advanced Solid ... | Sorafenib AMG 706 AMG 706 AMG 386 Sunitinib Bevacizumab AMG 386 | 18 Years - | Amgen | |
| Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | NCT04933539 | Multiple Myelom... | Dexamethasone Carfilzomib Daratumumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | NCT02076191 | Myeloproliferat... | Ruxolitinib Decitabine | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. | NCT00034489 | Breast Neoplasm... | pemetrexed gemcitabine | 18 Years - | Eli Lilly and Company | |
| Survival Analysis: TACE vs. Combination Therapy in HCC | NCT06261138 | Hepatocellular ... | Transarterial c... Systemic treatm... | 18 Years - 75 Years | Zhejiang University | |
| Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | NCT05472506 | Head and Neck S... Head and Neck C... Head Cancer Neck Cancer Head Cancer Nec... Neck Carcinoma | IK-175 + nivolu... | 18 Years - | Ikena Oncology | |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | NCT01091259 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Irinotecan Bevacizumab | 18 Years - | NYU Langone Health | |
| M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer | NCT04633252 | Cancer Of Prost... Prostate Neopla... | ADT Prednisone M7824 Docetaxel M9241 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma | NCT01868828 | Multiple Myelom... | PAD VCD ASCT | - 65 Years | Peking University People's Hospital | |
| T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy | NCT05361798 | Cancer Of Prost... | M9241 Stereotactic Bo... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma | NCT00277017 | Kidney Cancer | 5-Flourouracil,... | - | New Mexico Cancer Care Alliance | |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | NCT02584478 | Endometrial Car... Ovarian Carcino... Fallopian Tube ... Primary Periton... Cervical Carcin... | AL3818 Paclitaxel Pegylated Lipos... Topotecan Topotecan Carboplatin Paclitaxel AL3818 | 18 Years - | Advenchen Laboratories, LLC | |
| Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | NCT03475004 | Colorectal Canc... Metastatic Canc... | Pembrolizumab Bevacizumab Binimetinib | 18 Years - 99 Years | University of Colorado, Denver | |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | NCT03860272 | Advanced Cancer Angiosarcoma Colorectal Canc... Endometrial Can... Fibrolamellar C... Non-small-cell ... Ovarian Cancer Prostate Cancer | Botensilimab Balstilimab | 18 Years - | Agenus Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
